Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 8, 2018, Pages 605-617

  Tuttle, Katherine R ^a   Lakshmanan, Mark C ^b   Rayner, Brian ^c   Busch, Robert S ^d   Zimmermann, Alan G ^b   Woodward, D Bradley ^b   Botros, Fady T ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULAGLUTIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; FUSION PROTEIN; GLUCAGON LIKE PEPTIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT;

ADULT; AGED; ARTICLE; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREATITIS; PARALLEL DESIGN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; ANALYSIS; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN GLARGINE; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT FUSION PROTEINS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85048436169     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30104-9     Document Type: Article

References (29)

1. KDOQI, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49:suppl 2 (2007), S12–S154.
2. KDIGO, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
3. Davies, M, Chatterjee, S, Khunti, K, The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol 8 (2016), 61–81.
4. National Kidney Foundation, KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60 (2012), 850–886.
5. Tuttle, KR, Bakris, GL, Bilous, RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis 64 (2014), 510–533.
6. Moen, MF, Zhan, M, Hsu, VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 4 (2009), 1121–1127.
7. Jendle, J, Grunberger, G, Blevins, T, Giorgino, F, Hietpas, RT, Botros, FT, Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Revs 32 (2016), 776–790.
8. Davidson, JA, Brett, J, Falahati, A, Scott, D, Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 17 (2011), 345–355.
9. Tuttle, KR, Heilmann, C, Hoogwerf, BJ, Brown, C, Anderson, PW, Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis 62 (2013), 396–398.
10. Pawaskar, M, Tuttle, KR, Li, Q, Best, JH, Anderson, PW, Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Ann Pharmacother 48 (2014), 571–576.
11. Tuttle, KR, McKinney, TD, Davidson, JA, Anglin, G, Harper, KD, Botros, FT, Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab 19 (2017), 436–441.
12. Filippatos, TD, Elisaf, MS, Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 4 (2013), 190–201.
13. Tanaka, T, Higashijima, Y, Wada, T, Nangaku, M, The potential for renoprotection with incretin-based drugs. Kidney Int 86 (2014), 701–711.
14. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
15. Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
16. Mann, JFE, Ørsted, DD, Brown-Frandsen, K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
17. Inker, LA, Schmid, CH, Tighiouart, H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367 (2012), 20–29.
18. Levey, AS, Stevens, LA, Schmid, CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
19. Rosenstock, J, Fonseca, VA, Gross, JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 37 (2014), 2317–2325.
20. Blonde, L, Jendle, J, Gross, J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 385 (2015), 2057–2066.
21. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
22. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
23. Körner, M, Stöckli, M, Waser, B, Reubi, JC, GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48 (2007), 736–743.
24. Fujita, H, Morii, T, Fujishima, H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85 (2014), 579–589.
25. Imamura, S, Hirai, K, Hirai, A, The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med 231 (2013), 57–61.
26. Park, CW, Kim, HW, Ko, SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18 (2007), 1227–1238.
27. Muskiet, MHA, Tonneijck, L, Smits, MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13 (2017), 605–628.
28. Gutzwiller, JP, Tschopp, S, Bock, A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89 (2004), 3055–3061.
29. + exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297 (2009), F1647–F1655.